- Norstella (Washington, DC)
- …for someone who is passionate about unlocking business value with data and advanced analytics through partnership with technology and engineering + Experience in ... the complexities of healthcare to smooth access to life saving therapies . Our collective teams achieve this through prioritizing cultivating industry leading… more
- Sumitomo Pharma (Washington, DC)
- …and Europe, a diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate discovery, research, and ... rare diseases, psychiatry & neurology, and cell & gene therapies . With several marketed products in the US, Canada,...diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate… more
- Sumitomo Pharma (Washington, DC)
- …and Europe, a diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate discovery, research, and ... rare diseases, psychiatry & neurology, and cell & gene therapies . With several marketed products in the US, Canada,...diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate… more
- Sumitomo Pharma (Washington, DC)
- …and Europe, a diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate discovery, research, and ... rare diseases, psychiatry & neurology, and cell & gene therapies . With several marketed products in the US, Canada,...diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate… more
- Sumitomo Pharma (Washington, DC)
- …and Europe, a diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate discovery, research, and ... rare diseases, psychiatry & neurology, and cell & gene therapies . With several marketed products in the US, Canada,...diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate… more
- Sumitomo Pharma (Washington, DC)
- …and Europe, a diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate discovery, research, and ... rare diseases, psychiatry & neurology, and cell & gene therapies . With several marketed products in the US, Canada,...diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate… more
- Takeda Pharmaceuticals (Washington, DC)
- …forward-looking, world-class R&D organization that unlocks innovation and delivers transformative therapies to patients. By focusing R&D efforts on three therapeutic ... of what is possible in order to bring life-changing therapies to patients worldwide. Are you looking for a...organization, based remotely. + Partners with the Global Regulatory Lead (GRL) on Global Regulatory Teams (GRTs) to ensure… more
- Deloitte (Washington, DC)
- …looking for practitioners who will work alongside Life Sciences organizations from bio- technology firms to global big pharma to medical devices, to drive business ... + Develop enduring customer relationships through client engagement work + Lead follow-on business development efforts with existing engagements and client… more
- J&J Family of Companies (Washington, DC)
- …related aspects of developing and executing therapy awareness and education strategies for advanced treatment therapies + Must have experience and contacts in ... portfolio and robust pipeline provide us the incredible opportunity to bring lifesaving technology to more patients around the world than ever before. Founded in… more
- Danaher Corporation (Washington, DC)
- …biological research to developing innovative vaccines, new medicines, and cell and gene therapies . At Cytiva you will be able to continuously improve yourself and us ... collaborate to determine the funnel of high impact improvement priorities and lead the definition, maturity model, deployment and continuous improvement of DMS… more